Literature DB >> 17021816

PET imaging of apoptosis with (64)Cu-labeled streptavidin following pretargeting of phosphatidylserine with biotinylated annexin-V.

Nicole Cauchon1, Réjean Langlois, Jacques A Rousseau, Guillaume Tessier, Jules Cadorette, Roger Lecomte, Darel J Hunting, Roberto A Pavan, Stefan K Zeisler, Johan E van Lier.   

Abstract

PURPOSE: In vivo detection of apoptosis is a diagnostic tool with potential clinical applications in cardiology and oncology. Radiolabeled annexin-V (anxV) is an ideal probe for in vivo apoptosis detection owing to its strong affinity for phosphatidylserine (PS), the molecular flag on the surface of apoptotic cells. Most clinical studies performed to visualize apoptosis have used (99m)Tc-anxV; however, its poor distribution profile often compromises image quality. In this study, tumor apoptosis after therapy was visualized by positron emission tomography (PET) using (64)Cu-labeled streptavidin (SAv), following pre-targeting of apoptotic cells with biotinylated anxV.
METHODS: Apoptosis was induced in tumor-bearing mice by photodynamic therapy (PDT) using phthalocyanine dyes as photosensitizers, and red light. After PDT, mice were injected i.v. with biotinylated anxV, followed 2 h later by an avidin chase, and after another 2 h with (64)Cu-DOTA-biotin-SAv. PET images were subsequently recorded up to 13 h after PDT.
RESULTS: PET images delineated apoptosis in treated tumors as early as 30 min after (64)Cu-DOTA-biotin-SAv administration, with tumor-to-background ratios reaching a maximum at 3 h post-injection, i.e., 7 h post-PDT. Omitting the administration of biotinylated anxV or the avidin chase failed to provide a clear PET image, confirming that all three steps are essential for adequate visualization of apoptosis. Furthermore, differences in action mechanisms between photosensitizers that target tumor cells directly or via initial vascular stasis were clearly recognized through differences in tracer uptake patterns detecting early or delayed apoptosis.
CONCLUSION: This study demonstrates the efficacy of a three-step (64)Cu pretargeting procedure for PET imaging of apoptosis. Our data also confirm the usefulness of small animal PET to evaluate cancer treatment protocols.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17021816     DOI: 10.1007/s00259-006-0199-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  42 in total

1.  Process of apoptosis induced by TNF-alpha in murine fibroblast Ltk-cells: continuous observation with video enhanced contrast microscopy.

Authors:  K Okamoto; M Mizuno; N Nakahara; A Natsume; J Yoshida; T Mori; S Hori; H Kobayashi
Journal:  Apoptosis       Date:  2002-02       Impact factor: 4.677

Review 2.  Recent advances in pretargeted radioimmunotherapy.

Authors:  A Gruaz-Guyon; O Raguin; J Barbet
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

Review 3.  Pretargeted radioimmunotherapy of cancer: progress step by step.

Authors:  Otto C Boerman; Frank G van Schaijk; Wim J G Oyen; Frans H M Corstens
Journal:  J Nucl Med       Date:  2003-03       Impact factor: 10.057

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 5.  Targeted therapy of cancer with radiolabeled antibodies.

Authors:  David M Goldenberg
Journal:  J Nucl Med       Date:  2002-05       Impact factor: 10.057

6.  Efficacy and mechanism of aluminium phthalocyanine and its sulphonated derivatives mediated photodynamic therapy on murine tumours.

Authors:  W S Chan; N Brasseur; C La Madeleine; R Ouellet; J E van Lier
Journal:  Eur J Cancer       Date:  1997-10       Impact factor: 9.162

7.  Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.

Authors:  D B Axworthy; J M Reno; M D Hylarides; R W Mallett; L J Theodore; L M Gustavson; F Su; L J Hobson; P L Beaumier; A R Fritzberg
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

8.  Comparison between human pharmacokinetics and imaging properties of two conjugation methods for 99mTc-annexin A5.

Authors:  H H Boersma; I H Liem; G J Kemerink; P W L Thimister; L Hofstra; L M L Stolk; W L van Heerde; M-T W Pakbiers; D Janssen; A J Beysens; C P M Reutelingsperger; G A K Heidendal
Journal:  Br J Radiol       Date:  2003-08       Impact factor: 3.039

9.  The effects of photodynamic therapy using differently substituted zinc phthalocyanines on vessel constriction, vessel leakage and tumor response.

Authors:  V H Fingar; T J Wieman; P S Karavolos; K W Doak; R Ouellet; J E van Lier
Journal:  Photochem Photobiol       Date:  1993-08       Impact factor: 3.421

10.  Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application.

Authors:  Gerrit J Kemerink; Xuan Liu; Davy Kieffer; Sarah Ceyssens; Luc Mortelmans; Alfons M Verbruggen; Neil D Steinmetz; Jean-Luc Vanderheyden; Allan M Green; Kristin Verbeke
Journal:  J Nucl Med       Date:  2003-06       Impact factor: 10.057

View more
  20 in total

Review 1.  Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments.

Authors:  Y Waerzeggers; P Monfared; T Viel; A Faust; K Kopka; M Schäfers; B Tavitian; A Winkeler; A Jacobs
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 2.  Imaging and photodynamic therapy: mechanisms, monitoring, and optimization.

Authors:  Jonathan P Celli; Bryan Q Spring; Imran Rizvi; Conor L Evans; Kimberley S Samkoe; Sarika Verma; Brian W Pogue; Tayyaba Hasan
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

3.  Engineered annexin A5 variants have impaired cell entry for molecular imaging of apoptosis using pretargeting strategies.

Authors:  Lisette Ungethüm; Heidi Kenis; Gerry A Nicolaes; Ludovic Autin; Svetla Stoilova-McPhie; Chris P M Reutelingsperger
Journal:  J Biol Chem       Date:  2010-11-15       Impact factor: 5.157

4.  Defining the structural characteristics of annexin V binding to a mimetic apoptotic membrane.

Authors:  Jingxiong Lu; Anton P Le Brun; Seong Hoong Chow; Takuya Shiota; Bo Wang; Tsung-Wu Lin; Guei-Sheung Liu; Hsin-Hui Shen
Journal:  Eur Biophys J       Date:  2015-08-14       Impact factor: 1.733

5.  Role of small animal PET for molecular imaging in pre-clinical studies.

Authors:  Cristina Nanni; Domenico Rubello; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03-10       Impact factor: 9.236

Review 6.  Noninvasive imaging of apoptosis in cardiovascular disease.

Authors:  Ethan Chauncey Korngold; Farouc Amin Jaffer; Ralph Weissleder; David Edwin Sosnovik
Journal:  Heart Fail Rev       Date:  2008-06       Impact factor: 4.214

7.  Radiolabeling of Theranostic Nanosystems.

Authors:  Sudeep Das; Surachet Imlimthan; Anu J Airaksinen; Mirkka Sarparanta
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Measuring response to therapy by near-infrared imaging of tumors using a phosphatidylserine-targeting antibody fragment.

Authors:  Jian Gong; Richard Archer; Michael Brown; Seth Fisher; Connie Chang; Matthew Peacock; Christopher Hughes; Bruce Freimark
Journal:  Mol Imaging       Date:  2013-06       Impact factor: 4.488

9.  Choline PET for monitoring early tumor response to photodynamic therapy.

Authors:  Baowei Fei; Hesheng Wang; Chunying Wu; Song-mao Chiu
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

10.  Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics.

Authors:  Brian M Zeglis; Christian Brand; Dalya Abdel-Atti; Kathryn E Carnazza; Brendon E Cook; Sean Carlin; Thomas Reiner; Jason S Lewis
Journal:  Mol Pharm       Date:  2015-08-31       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.